EXT608
Phase 2Small molecule
EXT608 is one of 7 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Hypoparathyroidism
#DrugCompanyPhaseTrials
1Theo-Dur
PfizerApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Calciferol
Jazz PharmaceuticalsApproved
Calcium
Eli LillyPreclinical
EXT608
EExtend Biosciences Inc.
Phase 2
Intravenous Injection of 68ga-PMD22
PPeking Union Medical College Hospital
Phase 1
Yorvipath
Ascendis PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EXT608. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EExtend Biosciences Inc.